沙利度胺联合华蟾素治疗肝癌恶病质的临床研究

Clinical study on thalidomide combined with cinobufagin in the treatment of primary liver cancer cachexia

目的:探讨沙利度胺联合华蟾素治疗肝癌恶病质的临床价值.方法:筛选47例确诊肝癌恶病质患者,随机分为试验组及对照组.试验组给予沙利度胺150 mg/d+华蟾素胶囊2700 mg/d,对照组给予华蟾素胶囊2700 mg/d.观察两组患者营养状况、生活质量、生存期及副反应情况.结果:12周后华蟾素联合沙利度胺(试验组)可显著改善肝癌恶病质患者生活质量及生存期,且优于对照组,副反应发生率比对照组低,耐受性好.结论:沙利度胺联合华蟾素对抑制肝癌恶病质患者的营养状况、生活质量均有明显改善,优于单用华蟾素,且耐受性好,具有较高的临床价值.

AIM： To discuss and assess the clinical value of thalidomide combined with cinobufagin in the treatment of liver cancer cachexia. METHODS： A cohort of 47 patients diagnosed with liver cancer were randomly divided into trial group and con- trol group respectively. The trial group was given 150 mg/day tha- lidomide and 2700 mg/day cinobufagin; the control group only re- ceived 2700 mg/day cinobufagin. The therapy lasted for 12 weeks, and the nutritional status, quality of life, survival and side effects in patients of the two groups were recorded. RESULTS： The nutritional status, quality of life, and survival of patients with liver cancer cachexia in the trial group were significantly improved than those of the control group. The trial group received 150 mg thalidomide, which by contrast reduced the incidence of side effect and increased tolerance. CONCLUSION： Thalidomide combined with cinobufagin can improve nutritional status and quality of life of patients. The treatment effect is better than that of cinobufagin alone and is well tolerated, and it has higher value.